ArticleJournal of clinical medicine2023
The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Environmental and Neighborhood Determinants of Psoriasis: A Systematic Review of Pollution, Built Environment, and Socioeconomic Vulnerability on Psoriasis.Dermatology and therapy · 2026Pooled it
- Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review.International journal of dermatology · 2026Pooled it
- Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.Advances in therapy · 2025Trial
- A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings.The Australasian journal of dermatology · 2026Article
- Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study.EClinicalMedicine · 2026Article
- Insurance disparities in hidradenitis suppurativa: A comprehensive review of demographics, outcomes, and access to care.Dermatology online journal · 2026Review
- Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Social Determinants of Health as a Predictor of Psoriasis Risk: Preliminary Findings from a National Survey.Clinical, cosmetic and investigational dermatology · 2026Article
- Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling.BMC rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the introduction of biologics for psoriasis, uptake has been uneven and limited. Few studies have investigated the influence of socioeconomic factors on access to biologics.
objectiveTo investigate how socioeconomic factors influenced access to biologics.
methodsBiologic-naïve patients in the Swedish National Register for Systemic Treatment of Psoriasis (PsoReg) for the years 2006-2014 were included. For patients who remained on nonbiologic treatments during their entire registration (
resultsThe odds ratio of access to biologics was 1.8 (CI = 1.3-2.6) in the group with a high level of disposable income, compared with the middle-income group. No differences were found concerning educational levels. The odds ratios of access to biologics decreased with age. Patients with psoriatic arthritis had odds ratios of access to biologics which were more than 50 percent higher, controlling for other variables. High disease severity, in terms of physician- and patient-reported severity, increased the odds ratios of access to biologics.
conclusionsThe higher-income group had better access to biologics than the middle-income group when adjusting for disease severity and lifestyle factors. This may not only be an equity problem, as a better allocation of society's resources might have resulted in a higher overall effectiveness of biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.